CEACAM6 and familial pancreatic carcinoma: In addition, researchers have conducted the following studies: 1) the common uncontrolled microRNA in PDAC and the possible molecular targets in the signaling pathway of pancreatic cancer, 2) the use of nano-gene-silencing drugs to target drug-resistant patients with pancreatic cancer and duodenal homeobox 1 as a specific and potential RNAi target in pancreatic cancer, and 3) the use of siRNA to silence or inhibit kirsten rat sarcoma viral oncogene (KRAS) and abnormally expressed molecules (such as thrombin, CEACAM6, and EphA2).